← Back

Wire · operational-macro

Bayer won FDA approval for first-in-class stroke drug Sunharbo

Published

10 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at qz.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

Bayer obtained FDA approval for Sunharbo (asundexian), the first-in-class factor XIa inhibitor to reduce stroke recurrence risk in certain adults, marking a new option in anticoagulant therapy for non-cardioembolic ischemic stroke and high-risk transient ischemic attack patients.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You face a new market opening with Sunharbo providing a novel approach to stroke prevention that avoids cardioembolic cases. Stroke-focused neuro and biotech founders can shift attention to factor XIa inhibition as established players invest early in clinical uptake.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechstroke-drugfda-approvalbayeranticoagulantfactor-xia